Miravo Healthcare™ to Host Investor Webcast on December 2, 2021 at 2:00 p.m. ET

Rhea-AI Summary

Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF), operating as Miravo Healthcare, announced an investor presentation webcast scheduled for December 2, 2021 at 2:00 p.m. ET. CEO Jesse Ledger and CFO Mary-Jane Burkett will present key business insights, followed by a live Q&A session. Investors can pre-register for the event and will have access to an archived version on the company’s website afterward. Miravo focuses on healthcare with a diverse product portfolio targeting pain, allergy, and dermatology.

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it will host an investor presentation webcast on Thursday, December 2, 2021 at 2:00 p.m. ET (11:00 a.m. PT).

During the webcast, Jesse Ledger, President & Chief Executive Officer and Mary-Jane Burkett, Vice President & Chief Financial Officer of Miravo will provide a PowerPoint presentation that will cover key areas of Miravo’s business. During the presentation, investors will have an opportunity to ask questions through an interactive Q&A portal.

To access the webcast or to ask questions during the live event, please pre-register at the following link: https://event.webcasts.com/starthere.jsp?ei=1495546&tp_key=8127b0e5a0.

An archived version of the webcast and presentation will be available on the Presentations & Webcasts page of the Company’s website, https://www.miravohealthcare.com/investors/presentations-webcasts/ following the event.

About Miravo Healthcare

Miravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company’s products target several therapeutic areas, including pain, allergy, and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company’s manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S, Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration. For additional information, please visit www.miravohealthcare.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211118005530/en/

Investor Relations

Stefan Eftychiou

905 326 1888 ext 60

stefan@bristolir.com

Source: Nuvo Pharmaceuticals Inc.

FAQ

What is the date of the Miravo Healthcare investor presentation?

The investor presentation for Miravo Healthcare is scheduled for December 2, 2021.

What time does the Miravo investor webcast start?

The Miravo investor webcast will start at 2:00 p.m. ET on December 2, 2021.

Who will present during the Miravo Healthcare webcast?

Jesse Ledger, President & CEO, and Mary-Jane Burkett, CFO, will present during the webcast.

How can investors register for the Miravo Healthcare presentation?

Investors can pre-register for the Miravo Healthcare presentation through the provided link in the press release.

Will the Miravo Healthcare presentation be available later?

Yes, an archived version of the presentation will be available on the company's website following the event.

What is the focus area of Miravo Healthcare's products?

Miravo Healthcare focuses on therapeutic areas including pain, allergy, and dermatology.